Table 2.
Medications used during disease course
| Medication | Study Cohort n=25 (%) |
CARRA Registry Cohort n=389 (%) |
P Value |
|---|---|---|---|
| Biologic DMARDs | |||
| Abatacept | 2 (8) | 19 (6) | NS* |
| IL1 inhibitor (any) | 20 (80) | 168 (43) | <0.001 |
| Anakinra | 20 (80) | 156 (40) | <0.001 |
| Canakinumab | 3 (12) | 7 (2) | 0.018 |
| Rilonacept | 4 (16) | 27 (7) | NS |
| IVIG | 7 (28) | 24 (6) | 0.001 |
| Rituximab | 0 (0) | 7 (2) | NS |
| Tocilizumab | 5 (20) | 29 (8) | 0.044 |
| TNF inhibitor (any) | 15 (60) | 174 (45) | NS |
| Adalimumab | 5 (20) | 48 (12) | NS |
| Certolizumab | 0 (0) | 2 (1) | NS |
| Etanercept | 12 (48) | 140 (36) | NS |
| Golimumab | 0 (0) | 2 (1) | NS |
| Infliximab | 6 (24) | 54 (14) | NS |
| Glucocorticoids | |||
| Methylprednisolone pulses | 23 (92) | 122 (31) | <0.001 |
| Prednisone | 25 (100) | 336 (86) | NS |
| Non-biologic DMARDs | NR | ||
| Mycophenolate | 3 (12) | 12 (3) | NS |
| Cyclophosphamide | 5 (20) | 7 (2) | 0.001 |
| Cyclosporine | 14 (56) | 45 (12) | <0.001 |
| Etoposide | 5 (20) | NR | |
| Gold | 1 (4) | NR | |
| Methotrexate | 22 (88) | 232 (78) | NS |
| Penicillamine | 1 (4) | NR | |
| Tacrolimus | 2 (8) | 8 (2) | NS |
| Thalidomide | 4 (16) | NR |
NR = Not reported; IVIG = intravenous immunoglobulin; DMARD = disease modifying anti-rheumatic drug
*
NS: not significant with P> 0.05